Foghorn Therapeutics has been granted a patent for compounds designed to treat BAF complex-related disorders. The compounds have a specific structure outlined in the claim. GlobalData’s report on Foghorn Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
According to GlobalData’s company profile on Foghorn Therapeutics, Cancer treatment biomarkers was a key innovation area identified from patents. Foghorn Therapeutics's grant share as of January 2024 was 5%. Grant share is based on the ratio of number of grants to total number of patents.
Compounds for treating baf complex-related disorders
See Also:
A recently granted patent (Publication Number: US11851445B2) discloses a compound with a specific structure, as outlined in the claims. The compound is utilized in the creation of pharmaceutical compositions, as detailed in subsequent claims. The patent emphasizes the importance of the compound's structure in its application within pharmaceutical compositions.
The claims within the patent highlight the compound's structure and its role in pharmaceutical compositions. The specificity of the compound's structure indicates a unique and potentially valuable application within the pharmaceutical industry. By focusing on the compound's structure, the patent provides a clear framework for its utilization in the development of pharmaceutical compositions. This patent could potentially lead to advancements in drug development and treatment options, based on the specific compound outlined in the claims.
To know more about GlobalData’s detailed insights on Foghorn Therapeutics, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.